nuclear-medicine
(5)
RadioMedix and the cancer drugs that race the clock
A radioactive medicine has two jobs: find its target and arrive before its useful activity fades. RadioMedix has spent two decades working on both, from PET imaging to an investigational alpha therapy licensed to Sanofi.
MIM makes medical scans earn their keep
A scan can reveal a great deal and still leave a clinician with hours of work. MIM built a business in that awkward gap - and GE HealthCare bought it for a reported $283 million purchase price.
Alpha-9 Oncology
Alpha-9 Oncology is a clinical-stage radiopharmaceutical company engineering bespoke, tumor-targeting molecules that deliver alpha- and beta-emitting isotopes directly to cancer cells while sparing healthy tissue. Spun out of the University of British Columbia and BC Cancer in 2019 and now headquartered in Boston with research operations in Vancouver, the company iteratively optimizes each part of a radiopharmaceutical - binder, linker, chelator and radioisotope - to build a pipeline of paired imaging and therapy candidates. Backed by $258M in total funding, including a $175M Series C in 2024, Alpha-9 aims to expand precision radiotherapy across validated oncology targets.
AdvanCell
AdvanCell is a vertically integrated, clinical-stage radiopharmaceutical company developing a pipeline of targeted alpha therapies (TAT) for cancer, powered by its proprietary Lead-212 (212Pb) alpha isotope generator technology. By solving the chronic supply bottleneck of alpha-emitting isotopes, AdvanCell aims to deliver highly potent, tumor-specific radiation that destroys cancer cells while sparing healthy tissue. Its lead asset, ADVC001, a 212Pb-PSMA therapy, is in clinical trials for metastatic prostate cancer, with a deepening pipeline targeting melanoma, ovarian, breast, and lung cancers.
Bill Cupelo
Bill Cupelo is the Chief Business Officer of Ratio Therapeutics, a Boston-based biotech building targeted radiopharmaceuticals that aim to both image and treat cancer. A chemist by training who learned to sell science, he spent more than a decade at imaging CRO Invicro, climbing from software product manager to head of sales, before bringing his sponsor-side, science-first mindset to Ratio's pipeline of alpha-emitting radioligand therapies. He also serves as Treasurer of the Massachusetts Nuclear Medicine & Radiopharmaceutical Council.